BusinessWire · Dec 2025
Valink and Nona announced a strategic biologics discovery alliance branded 'Biology to Bispecific' to combine Nona’s antibodies with Valink’s LiliumX platform for bsADC discovery, with an initial focus on solid tumors.
Discovering bispecific antibody drug-conjugates (BsADC) against cancer
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Valink Therapeutics is a University of Oxford spinout and private biotechnology company developing first-in-class bispecific antibody-drug conjugates (bsADCs) for oncology, using its LiliumX modular discovery platform and V-Gate target-gating approach.
Primary product
Bispecific antibody-drug conjugates (bsADCs) built with the LiliumX platform
Founded
2021
Headquarters
One Broadway, Cambridge, Massachusetts 02142, United States
Team size
20-30
Industry
Biotechnology Research
Sub-industry
Oncology therapeutics / bispecific antibody-drug conjugates
Offices
One Broadway, Cambridge, Massachusetts 02142, United States
Imperial I-Hub, 84 Wood Lane, London, W12 0BZ, United Kingdom
Business model
proprietary drug discovery platform
oncology therapeutics development
co-development partnerships
licensing / out-licensing
Funding
Stage
Pre-A
Total raised
$19.7M
Latest round
Pre-A financing · Oct 2025
Latest amount
$11.8M
Oct 2025 · redalpine
Nov 2023 · RV Invest
People & investors
Leadership
Co-Founder & CEO
Co-Founder & CTO
VP, ADC Chemistry & Engineering
Director of BD & Strategy
Director of Operations
Chair of the Board of Directors
Work & culture
Company messaging emphasizes diversity and equal opportunity, an open-minded approach to science, and a collaborative research culture spanning Greater Boston and the UK Golden Triangle.
Compensation
A public job listing described competitive salary at Director/Principal level, stock options, and benefits including 25 days holiday, private medical insurance, life assurance, matched pension, flexible hours, hybrid working, Cyclescheme, and wellbeing support. Company-wide compensation bands are not public.
Benefits
stock option plan
25 days holiday plus bank holidays
private medical insurance
life assurance
matched pension
flexible working hours
hybrid working
Cyclescheme
wellbeing engagement
competitive salary
Product & market
Pricing
Partnership-driven platform and therapeutics model, with co-development and licensing opportunities; no public list pricing.
Differentiators
- —Modular LiliumX screening of targets, binders, formats, linkers, and payloads
- —V-Gate approach that goes beyond binary target gating
- —AI plus curated disease datasets for molecular design
- —Rapid high-throughput bsADC generation and screening
- —Broader modality work beyond bsADCs, including dual payload, trispecific, and multivalent platforms
Technology
LiliumX modular discovery platform
V-Gate target-gating approach
synthetic protein biology
high-throughput functional screening
AI-assisted molecular design
protein engineering
synthetic biology
automation
curated disease datasets
dual payload conjugation
trispecific ADC design
multivalent antibody platforms
multivalent agonists
Competitors
DualityBio
Avenzo Therapeutics
SystImmune
Alphamab Oncology
BiVictriX Therapeutics
InduPro
Genmab
Scale & contact
Estimated revenue
~$2.6M ARR (estimated public profile)
Estimated monthly visits
1.6K
Traffic estimate as of Jun 2026
Latest news
BusinessWire · Oct 2025
Valink announced an $11.8M Pre-A round led by redalpine with participation from LongeVC, Oxford Science Enterprises, and existing backers; proceeds support its oncology pipeline and U.S. expansion.
Valink · Dec 2024
Valink appointed Martin D. Williams as board chair and named a scientific advisory board to support ADC and bispecific development.
Valink · Jul 2024
Arne Scheu presented Valink’s bsADC discovery approach at Curious2024, highlighting rapid modular assembly and screening of candidates.
Valink · Jun 2024
Irsyad Khairil represented Valink at a London Stock Exchange / DBT health-tech showcase.
Jobs and careers at Valink Therapeutics
0 jobs at Valink Therapeutics
No open positions
Check back later for new openings